GILEAD SCIENCES, INC.
GILDPharma & biotechgilead.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 30, 2026
Next reportFebruary 8, 2027after close · forecast 1.49 $/share
Revenue
$8.30B
▲ +6.8% vs prior year YoY
Net income
$2.43B
▼ -20.4% vs prior year YoY
EPS
1.94$
▼ -20.2% vs prior year YoY
Net margin
29.3%
▼ -10.0 pp vs prior year YoY
Revenue▲ +6.8%
Margins (% of revenue)GrossOperatingNet
Net income▼ -20.4%
EPS▼ -20.2%
Financial statements
View 10-Q filed October 30, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B | $6.96B | $7.80B | $8.30B | ▲ +6.8% |
| Gross profit | $5.99B | $5.13B | $5.58B | $6.20B | $6.30B | $5.51B | $6.22B | $6.73B | ▲ +8.5% |
| Operating income | $2.45B | $2.24B | $2.47B | $3.33B | $1.98B | $2.59B | −$10.39B | $3.46B | ▲ +4.1% |
| Net income | $1.78B | $1.31B | $1.96B | $3.05B | $2.18B | $2.02B | −$10.50B | $2.43B | ▼ -20.4% |
| R&D | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 1.04 $ | 1.56 $ | 2.43 $ | — | 1.61 $ | -8.45 $ | 1.94 $ | ▼ -20.2% |
| Margins (% of revenue) | |||||||||
| Gross | 79.1 % | 76.9 % | 78.8 % | 79.8 % | 79.5 % | 79.2 % | 79.8 % | 81.1 % | ▲ +1.3 pt |
| Operating | 32.4 % | 33.6 % | 34.9 % | 42.8 % | 25.0 % | 37.2 % | -133.2 % | 41.7 % | ▼ -1.1 pt |
| Net | 23.6 % | 19.7 % | 27.7 % | 39.3 % | 27.5 % | 29.0 % | -134.5 % | 29.3 % | ▼ -10.0 pt |
| Balance sheet | |||||||||
| Assets | $58.99B | $56.43B | $55.72B | $58.53B | $59.02B | $56.28B | $49.36B | $51.41B | ▼ -12.2% |
| Liabilities | $39.75B | $37.36B | $36.13B | $37.08B | $36.41B | $32.85B | $37.62B | $38.45B | ▲ +3.7% |
| Equity | $19.25B | $19.08B | $19.59B | $21.46B | $22.62B | $23.43B | $11.74B | $12.96B | ▼ -39.6% |
| Cash | — | — | — | — | — | — | — | — | — |
| Capital | |||||||||
| Shares outstanding | 1.25B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | ▼ -0.0% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.